Celiac disease (CD) is a chronic enteropathy triggered by exposure to dietary gluten in genetically susceptible individuals. The only currently accepted therapy for CD is a lifetime gluten-free diet (GFD). Although a GFD has proven to be a safe and effective in most celiac patients, there are limitations that warrant new adjuvant therapies for the treatment of CD. The therapies in development for CD fall into the following categories 1) Gluten detoxification 2) Luminal therapies 3) Intestinal barrier enhancing therapies 4) Immune targeted therapies and 5) Experimental therapies. Gluten detoxification includes altering gluten proteins in foods before commercialization. Luminal therapies aim at neutralizing gluten in the lumen of the small intestine. These include enzymatic digestion therapy, probiotics and gluten binders. Barrier enhancing therapies decrease the leaky intestinal condition associated with the disease, which could enhance translocation of gluten peptides, or of other harmful antigens, into the lamina propria. Immune targeted therapies include TG2 blockers, HLA blockers, T cell targeted therapies, alteration of inflammatory mediators and vaccine therapy. Finally, experimental therapies comprise compounds or biological strategies in discovery phase. Of these, Elafin was recently proposed to play a role in CD and have potential therapeutic applications in an animal model. To date, none of the discussed therapies have been approved for clinical use and are at different stages of development. However, adjuvant therapies to the GFD will likely become a reality to the coming years and will increase the quality of life of patients living with gluten-related disorders.
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Introduction
Celiac disease (CD) is a chronic autoimmune enteropathy triggered by exposure to dietary gluten in genetically susceptible individuals. Patients with a diagnosis of CD need to adopt a strict gluten-free diet (GFD) for life 1 . A GFD leads to significant clinical and histological improvement in CD patients, although it often results in social burden. This diet is expensive, not readily available in many countries, and if not properly supervised, may lead to nutritional deficiencies, which can affect the patient's quality of life. A gluten-containing diet based on consumption of cereals such as wheat, rye and barley is an important source of iron, dietary fibre and vitamin B [2] [3] [4] . A major problem underlying compliance with the GFD resides in the difficulty of complete avoidance of gluten 5 since its presence in processed foods, as well as its use in cosmetics and pharmaceutical industries, is ubiquitous. Gluten may be present in non-starchy foodstuff such as soy sauce and beer, and thus CD patients can be exposed inadvertently to small amounts of gluten that generate inflammation 6 . Furthermore, studies have shown that mucosal recovery is not immediate upon the start of a GFD, and that a substantial proportion of CD patients exhibit long-lasting low-grade inflammatory changes in the small intestinal mucosa [7] [8] [9] [10] . Therefore, although a GFD has proven to be a safe and effective therapy, the limitations described above warrant that new adjuvant therapies are needed in the treatment of CD.
Based on the current understanding of the pathogenesis of CD, several potential therapeutic targets are being explored and many reviews have recently been written on this topic [11] [12] [13] . The aim of this chapter is to summarize the current approaches and discuss the recent progress in the development of potential adjuvant treatments for CD.
Gluten Detoxification
Wheat gluten and related proteins in barley and rye trigger CD in genetically susceptible people. The complete elimination of gluten proteins contained in cereals from the diet is key to CD management 14 . Currently, novel techniques are being developed to generate cereal varieties with lower immunogenic or toxic capacity for CD patients. Selective breeding and genetic manipulation of the disease-activating grains have been proposed to reach this goal [15] [16] [17] . The use of genetic engineering to down-regulate gene expression by RNA interference is an attractive opportunity for reducing the immunotoxic components of gluten. This technology has been applied to down-regulate the expression of gliadins and low molecular weight glutenins in bread wheat.
Results have shown the usefulness of RNAi to silence specific genes corresponding to gluten proteins, which are the known sources of immunogenic peptides [18] [19] [20] [21] [22] . Flour from these lines may be an important breakthrough in the development of new products for the celiac community.
However, additional studies, such as clinical trials in patients with gluten-related disorders are needed in order to determine whether or not the product can be consumed by the general celiac population 18, 23 .
An alternative approach to detoxify gluten is the digestion of immunogenic gluten peptides with peptidases during food processing and before administration to CD patients 24 . Unlike mammalian digestive proteases, proteolytic enzymes from plants, fungi and microorganisms can hydrolyze toxic peptides in foods to amino acids or non-toxic peptides 25 . Di cagno et al.
(2010) have isolated Lactobacillus strains from sourdough bread that showed considerable hydrolysis of gliadin during wheat sourdough fermentation and investigated a novel bread making method for the production of safe sourdoughs 26 . Similarly, Rizello et al. (2007) showed that fermentation with a complex formula of sourdough Lactobacillus and fungal proteases decreased the concentration of gluten considerably. This wheat flour hydrolyzed during food processing was shown to be safe for consumption by CD patients in a clinical study 27, 28 . Although results with RNA interference and proteases in sourdough fermentation are promising, one important question is how baking quality will be affected and whether widespread consumption of these foods by CD patients will be safe 14, 15, 23 .
Luminal Therapies

Enzymatic Therapy
Gluten proteins are poorly digested in the human intestine because they are relatively resistant to human proteolytic enzymes. As a consequence, the gastrointestinal digestion of gluten leads to the generation of toxic peptides which trigger inflammation in genetically susceptible individuals 29 . Thus, oral enzymatic therapy is focused on inactivating immunogenic gluten peptides in the human gastrointestinal tract 30, 31 . The most commonly studied enzymes with the ability to carry out this process are proteases from the prolyl endopeptidase family (PEPs) which are not present in humans. PEPs from Flavobacterium meningosepticum, Sphingomonas capsulata and Myxococcus xanthus are able to cleave immunodominant proline-rich regions present in gluten proteins [32] [33] [34] .
For these enzymes to be effective, they must be resistant to both the acidic environment and digestive proteases of the stomach. Also, the majority of the epitope hydrolysis should occur in the stomach, to avoid toxic peptides entering the small intestine and triggering immune responses. Although encapsulation of PEPs was proposed in order to protect them from gastric secretions, recent studies have shown that only high doses of PEPs are capable of eliminating immunogenic peptides in a daily gluten load 35, 36 . AN-PEP is an enzyme derived from Aspergillus niger that is being developed by an alimentary company (DSM) 37 . In vitro studies have shown that AN-PEP is active at acidic pH, resists digestion by pepsin and degrades all tested gluten peptides with a half-life ranging between 2 and 6 minutes 34, 38 .
Based on these in vitro findings, a number of in vivo studies are underway in CD patients. Although AN-PEP appears to be well tolerated in CD patients, clinical improvements in these patients are not clear 39 . (ClinicalTrials.gov Identifier: NCT01335503). Another drug candidate, ALV003, is being developed as an orally administered mixture of two glutenases (ALV001 and ALV002) 40 . ALV001 is a glutamine-specific cysteine endoprotease derived from germinating barley seeds (EP-B2) and ALV002 is a PEP from Sphingomonas capsulata 33, 41 . Both enzymes are active in the acidic environment of the stomach, and a 1:1 (w/w) formulation (ALV003) maximizes their glutenasic activity 33 . Phase 1 and Phase 2a clinical trials have been performed in CD patients receiving ALV003. These studies demonstrated that ALV003 can attenuate gluten-induced small intestinal mucosal injury and decrease the immune response to gluten in CD patients, but ALV003 did not improve the clinical response (NCT00959114 and NCT01255696) 42, 43 . A Phase 2b, randomized, double-blind, placebo-controlled dose-ranging study of the efficacy and safety of ALV003 treatment in symptomatic CD patients maintained on a GFD is currently underway (ClinicalTrials.gov Identifier: NCT01917630). A third protease mixture (STAN 1) has been tested in a Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT00962182). STAN1 is a cocktail of microbial enzymes commonly used in food supplements that showed modest gluten detoxification capacity 31, 44 . The study evaluated the effect of STAN1 in CD patients ingesting 1 g of gluten per day for 12 weeks.
No differences were found in serology between the placebo group and the patients treated with STAN1 44, 45 . A common setback with oral enzyme therapy seems to be the need for sufficiently active enzyme delivery to allow interaction with immunogenic gluten peptides present in a daily gluten load.
However, although these enzymes may not eliminate the need for a GFD, they may provide substantial flexibility and prevention of detrimental side effects from lower gluten exposures, reducing long term complications of delayed mucosal healing 12 . A live commensal or beneficial bacterium that produces gluten-specific proteolytic molecules in situ would be an attractive alternative.
Probiotic Therapy
"Probiotics are defined as live microorganisms that when administered in adequate amounts confer health benefits to the host" 46 . Probiotics show a variety of immuno-modulatory, barrier enhancing and even mood-modulating effects that may be attractive to CD patients [47] [48] [49] . The probiotic preparation VSL#3 has been shown to hydrolyze gliadin proteins in vitro and may produce pre-digested gliadins during food processing 50 . Other studies with cell cultures and mouse models of gluten sensitivity have demonstrated that "particular probiotic bacteria such as Bifidobacterium lactis or Lactobacillus casei could be of potential use in CD" [51] [52] [53] . Administration of a specific Bifidobacterium infantis strain to patients with active CD (ClinicalTrials.gov identifier: NCT01257620) led to improvement in CD-associated symptoms accompanied by immunogenic changes, without a significant change in intestinal permeability 54 .
Another suggested alternative to facilitate gluten degradation and immune modulation includes the use of whole cultured bacteria from the human gastrointestinal tract. A number of studies from different groups have described substantial differences in the intestinal microbiota of patients with CD [55] [56] [57] . Bifidobacterium longum CECT7347 is a probiotic bacterial strain isolated from a healthy breastfed child with anti-inflammatory effects and proteolytic activity toward gliadin peptides in vitro [58] [59] [60] . To date, a double-bind, randomized, placebo-controlled intervention trial to evaluate the . This may raise discussions on the public acceptability of GMO's, despite the fact these have been shown to be safe for administration to mice and humans 66, 67 .
Gluten Binding Polymer: BL-7010
The gluten binding polymer, BL-7010 or copolymer poly(hydroxythyl methacrylate-co-styrene sulfonate (P(HEMA-co-SS) is a non-absorbable polymer that binds with high specificity to gliadin or gluten, intraluminally. 
Barrier Enhancing Therapies
CD is associated with altered barrier 70 and disrupted tight junction (TJ) function 71, 72 . The mechanisms for gluten peptide translocation in CD are controversial, and several pathways have been proposed 73, 74 . One is related to increases in paracellular uptake and increases in the release of zonulin, an endogenous modulator of TJs 75 . Zonulin has been reported to be regulated by 
Immune Targeted Therapies
There are several immune therapies under development for chronic gastrointestinal inflammation that could be applied to CD. Some target CD specific pathways, other target inflammatory mediators common in gastrointestinal inflammation. For instance, drugs for the treatment of inflammatory bowel disease (IBD) could be useful in CD 44 . On the other hand, immune specific therapies for CD include transglutaminase-2 (TG2) blockers, human leukocyte antigen (HLA) blockers, anti-IL-15 monoclonal antibodies and vaccine approaches 25 . 
TG2 Blockers
HLA Blockers
The genetic component of CD, the HLA-DQ2/8 molecules, are required for the development the disease, making them a desirable target for therapies.
HLA blockers have been attempted as a therapy in other diseases, such as multiple sclerosis and rheumatoid arthritis 25 . The major drawback of these therapies was the inability of the HLA blocker to reach the diseased site.
However, the rationale for treating CD with HLA blockers is the ease of accessibility to the site of disease (small intestine) 25 . Therefore, researchers are developing molecules with similar structure to gliadin that do not elicit an immune response because they are not recognized by gluten-specific T cells. 
T cell Targeted Therapies
T cells play a critical role in the pathology of CD, being responsible for the proinflammatory immune response and villus atrophy 89 . There are no current T cell mediated therapies that are being developed specifically for CD. Anti- 
Alteration of Inflammatory Mediators
A proportion of patients with CD have increased levels of IL-15. IL-15 plays a critical role in IEL cell activation and is an important cytokine linking the innate and adaptive immune response in CD 91, 92 . Therefore, blocking the actions of IL-15 in individuals with IL-15 driven CD is an attractive target. It has been shown that destruction of the small intestine can be reversed when blocking IL-15 with a monoclonal antibody in mice in vivo 
Vaccine Therapy
Vaccine therapy for CD is based on the concept that immune tolerance to an antigen can be induced by repetitive exposure to that same antigen. . NEXVAX2 is only specific to HLA-DQ2 individuals (90% of the CD population) 25, 99 . Of the therapies currently in development, the vaccine approach would be curative if proven efficacious.
Experimental Therapies
Necator americanus
The parasite Necator americanus is a human gastrointestinal nematode or hookworm believed to infect over 500 million people worldwide 100 . Infection with this hookworm has no major side effects, and is associated with normal mucosal appearance in duodenal biopsies 101 . However, the development of anemia may be of concern, as the parasite feeds on host blood (0.03-0.08 mL per day) 100 . 
Elafin
Elafin, an anti-inflammatory serine protease inhibitor, is decreased in the colon of patients with inflammatory bowel disease, and delivery of elafin to mice alleviated chemical-induced colitis 106 . Recently, the decreased mucosal expression of elafin in the small intestine of patients with active CD was described 92 . Also, delivery of elafin to the small intestine via the food grade bacterium Lactobacillus lactis, ameliorated immune and pathological responses to gluten in a mouse model (NOD-DQ8) that develops decreased villus-to-crypt ratios, anit-gliadin and anti-tissue TG2 antibodies upon sensitization 107 . Future research will need to determine the optimal delivery mode of this molecule to humans and its clinical efficacy.
Discussion and Conclusion
In summary, there are many therapies being developed for CD, which target different mechanisms of the disease process. Many of these therapies are already being tested in clinical trials, others are at discovery level of development. At the time this chapter was written, the most advanced therapy in clinical trial testing was the barrier enhancing therapy, AT-1001.
However, it cannot be predicted that this will be the first drug to be approved for clinical use. Even when one or more drugs for CD are approved in the future years, further testing will be required to investigate whether combination therapies are more efficacious than single therapies. concern is whether availability of these therapies could encourage patients to abandon the gluten-free diet. Guidelines for the "adjunctive" use of these therapies with the GFD will need to be clearly established. These drugs may also prove effective in other gluten-related disorders, and this will require further research. We are approaching exciting years in the pharmacological management of gluten-related disorders. Availability of one or more of the described therapies will increase the quality of life of patients living with gluten-related disorders. 
